Skip to main content
Download PDF

Rhodiola crenulata extract regulates hepatic glycogen and lipid metabolism via activation of the AMPK pathway

BMC Complementary and Alternative Medicine volume 16, Article number: 127 (2016) Cite this article

Abstract

Background

Metabolic syndrome may lead to many complications, such as nonalcoholic fatty liver disease (NAFLD). A natural and effective therapeutic agent for patients with NAFLD is urgently needed. In a previous study, we showed that Rhodiola crenulata root extract (RCE) regulated hepatic gluconeogenesis through activation of AMPK signaling. However, the manner in which RCE regulates hepatic lipid and glycogen metabolism remains unclear. The current study was conducted to investigate the effects of RCE on hepatic glycogen and lipid metabolism, as well as the mechanisms underlying such effects.

Methods

Human hepatoma HepG2 cells were treated with RCE for 6 h under high glucose conditions, after which glycogen synthesis, lipogenesis, and relative gene expression were examined. In addition, lipogenesis-related genes were investigated in vivo.

Results

RCE significantly increased glycogen synthesis and inhibited lipogenesis, while regulating genes related to these processes, including glycogen synthase kinase 3β (GSK3β), glycogen synthase (GS), fatty acid synthase (FAS), CCAAT/enhancer-binding protein (C/EBP), and sterol regulatory element-binding protein 1c (SREBP-1c). However, the effects caused by RCE were neutralized by compound C, an AMPK antagonist. Further studies showed that expression levels of lipogenic genes decreased at the protein and mRNA levels in the rat liver.

Conclusions

Our results demonstrate that RCE regulates hepatic glycogen and lipid metabolism through the AMPK signaling pathway. These results suggest that RCE is a potential intervention for patients with NAFLD.

Peer Review reports

Background

Modern lifestyles have resulted in a sharp increase in the occurrence of metabolic syndrome in recent decades. Metabolic syndrome is primarily caused by insulin resistance and associated with obesity and central fat distribution [1]. In addition, metabolic disorder may subsequently develop into cardiovascular disease and type II diabetes mellitus [2]. Thus, it has become a major public health concern in developed nations [3]. Insulin resistance contributes to excessive concentrations of free glucose and fatty acids in the circulatory system, which may cause increased oxidative stress, release of inflammatory cytokines, impaired β-oxidation of free fatty acids, and abnormal metabolism [4]. Among the effects of insulin resistance, abnormal hepatic glucose and lipid metabolism are the major causes of metabolic syndrome. One of the consequences of insulin resistance is redirection of excess glucose to de novo lipogenesis instead of glycogen synthesis in the liver [5]. Increased de novo lipogenesis leads to fat accumulation in the liver and is linked to the pathological progression of cirrhosis, nonalcoholic fatty liver disease (NAFLD), hepatitis, and liver cancer [6]. Thus, reduction of excessive hepatic lipidosis is an urgent concern for patients with metabolic syndrome.

Enhanced lipogenesis and decreased glycogen synthesis are hallmarks of hepatic insulin-resistance, which might subsequently lead to the development of type II diabetes mellitus [7]. The liver is the primary organ responsible for glycogen and lipid metabolism. Biosynthesis of glycogen and lipids is the primary means by which the body stores excess nutrients and is strictly controlled by a complex network of hormones and metabolic signals. Under normal conditions, glycogen is the primary storage form of excess energy. Glycogen production is regulated primarily via enzymes critically involved in glycogen metabolism, including glycogen synthase kinase 3β (GSK3β) and glycogen synthase (GS) [8]. However, insulin resistance shifts the major form of energy storage from glycogen to triglycerides (TG) in the liver [9], consistent with reduced GS activity in patients with type II diabetes [10]. These shifts in energy storage mechanisms increase lipogenesis, enhance cholesterol synthesis, and decrease fatty acid β-oxidation; eventually, such effects may lead to lipotoxicity-induced pancreatic β-cell dysfunction and metabolic syndrome [11].

5′ AMP-activated protein kinase (AMPK) coordinates many different signaling pathways involved in maintenance of energy homeostasis. AMPK is the switch controlling activation of anabolic and catabolic pathways [12]. AMPK regulates lipid metabolism by inactivating acetyl-CoA carboxylase (ACC) and 3-hydroxy-3-methylglutaryl-CoA reductase, resulting in increased lipid oxidation and inhibited cholesterol synthesis [13]. Thus, AMPK activation in the liver suppresses gluconeogenesis, lipogenesis, and cholesterol synthesis. Based upon its function, many studies have suggested that AMPK might be a therapeutic target for treatments for patients with insulin resistance and type II diabetes mellitus [12, 14, 15].

Rhodiola crenulata has been used in the traditional Chinese medicine system as a treatment for high altitude illness and diabetes, as well as in tonics [16, 17]. R. crenulata root extract (RCE) was recently shown to attenuate abnormal lipid metabolism and improve insulin sensitivity in a rodent model of diabetes [18]. In a previous study [19], we showed that RCE suppressed hepatic gluconeogenesis via activation of AMPK signaling. Our results also imply that RCE might suppress hepatic lipogenesis by inactivating key enzymes involved in lipogenesis, including fatty acid synthase (FAS) and ACC [20]. Although these results indicate that RCE is able to ameliorate abnormal glucose and lipid metabolism, the underlying mechanism of RCE requires further elucidation. The goal of the current study is to examine the effects of RCE on hepatic glycogen and lipid metabolism in human HepG2 cells and Sprague–Dawley (SD) rats, as well as to investigate the mechanisms underlying such effects.

Methods

Preparation and quantification of RCE

Preparation and analysis of RCE were described in a previous study by our group [19]. Briefly, Rhodiola crenulata (Hook. f. & Thomson) H. Ohba roots were obtained from Chuang Song Zong Pharmaceutical Co., Ltd (Kaohsiung,Taiwan). A voucher specimen (NDMCP no.1000901) was deposited in the National Defense Medical Center. The identity of R. crenulata was confirmed using the Plant List database. The drug-extract ratio of RCE was 6.25:1. HPLC showed that the RCE contained 3.5 % salidroside.

Cell culture and animal experiments

Human HepG2 cells [21] were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in DMEM medium (Gibco Laboratories, Grand Island, NY, USA). Male SD rats were employed in this study as described in a previous study by our group [19]. Briefly, cells were treated with different concentrations of RCE under high glucose conditions (33 mM) for 16 h. SD rats were fed RCE (50 mg/kg, suspended in 1 mL saline) or 1 mL saline by gavage once daily for 3 days, after which the animals were sacrificed and livers were collected. All of these procedures were proven by the Institutional Animal Care and Use Committee of the National Defense Medical Center (IACUC-11-055).

Glycogen synthesis assay

The glycogen synthesis assay was performed as described in a previous study [22]. Briefly, the assay was carried out with 5.5 mM glucose (2 Î¼Ci/mL, [14C]-d-glucose) for 30 min at 37 Â°C, followed by lysis with 0.5 N NaOH and measurement of the radiation intensity of glycogen via scintillation counting (Packard).

Lipogenesis assay

The lipogenesis assay in HepG2 cells was performed using a commercial kit (Cayman Chemical Co.) [23]. Briefly, cells were cultured in 24-well plates, after which 75 μL of Oil Red O solution was added to each well for 15 min. Subsequently, dye extraction solution was added to each well for 20 min. Finally, the absorbance of the solution in each well was measured at 490 nm using an ELISA microplate reader (Spectra Max 190, Molecular Devices).

Quantitative analysis of lipid metabolic gene expression

Relative gene expression levels of lipogenic enzymes were measured by quantitative real-time PCR (Q-PCR) as described previously [19]. The PCR primers are listed in Table 1.

Table 1 Oligonucleotide sequences used in this study
Full size table

Western blotting

Western blotting was performed as described in a previous study by our group [24]. Briefly, immunoblotting was performed using antibodies against AKT, phosphorylated AKT (Thr308 and Ser473, Santa Cruz, CA), CCAAT/enhancer-binding protein (C/EBP), AMPK, phosphorylated AMPK (T172), ACC, phosphorylated ACC (Cell Signaling Tech.), GSK3β, phosphorylated GSK3β (Abcam, Cambridge, MA), GS, phosphorylated GS (Ser641), β-actin (Chemicon, Temecula, CA, USA), and sterol regulatory element-binding protein 1c (SREBP-1c) (Gene Tex, Irvine, CA).

Statistical analysis

All results are presented as mean ± SEM. Significant differences between group means were determined using one-way ANOVA followed by Bonferroni’s post-hoc test. Analyses were performed using IBM SPSS Statistics version 22 (IBM® SPSS® Statistics 22). Differences were considered to be statistically significant when p-values were less than 0.05.

Results

RCE significantly increases AMPK and ACC phosphorylation

To clarify the regulatory effect of RCE on AMPK signaling in the liver, HepG2 cells were incubated with RCE. RCE significantly increased AMPK phosphorylation at T172 (1.51 ± 0.19, 1.73 ± 0.14, 1.73 ± 0.17, and 1.64 ± 0.25-fold over the control sample for 1.5, 3.0, 15.0, and 30.0 μg/mL, respectively; p < 0.05, p < 0.001, p < 0.01, and p < 0.05, respectively; Fig. 1a and b). ACC, a major substrate of AMPK, is involved in modulating hepatic lipogenesis, which suppresses conversion of acetyl-CoA to malonyl-CoA and subsequently leads to decreased fatty acid synthesis [25]. ACC phosphorylation following RCE treatment was concentration-dependent (1.31 ± 0.12, 1.76 ± 0.32, 1.65 ± 0.12, and 1.54 ± 0.11-fold over the control sample for 1.5, 3.0, 15.0, and 30.0 μg/mL, respectively; p < 0.05, p < 0.05, p < 0.001, and p < 0.001, respectively; Fig. 1a and c). These results indicate that pretreatment with RCE significantly increased the activity of the AMPK-ACC signaling pathway in HepG2 Cells without cytotoxicity under the chosen experimental conditions [19].

Fig. 1
figure 1

Effect of RCE on phosphorylation of AMPK and ACC in HepG2 cells.HepG2 cells were incubated in high-glucose medium (33 mM) for 16 h prior to the addition of the indicated concentrations of RCE or AICAR (2 mM). After pretreatment with RCE (μg/mL) for 6 h or AICAR for 2 h, p-AMPK and p-ACC expression levels were analyzed by western blotting (a). A quantitative analysis of the relative levels of p-AMPK (b) and p-ACC (c) was conducted. The results represent the mean ± SEM (n = 3), ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 vs. the sample without RCE

Full size image

RCE enhances de novo glycogen synthesis and expression of regulatory enzymes

To investigate the impact of RCE on glycogen synthesis, HepG2 cells were preincubated with RCE for 6 h. As shown in Fig. 2a, RCE at concentrations of 1.5, 3.0, 15.0, and 30.0 μg/mL significantly increased hepatic glycogen synthesis under high glucose conditions (1.14 ± 0.02, 1.37 ± 0.02, 1.40 ± 0.08, and 1.33 ± 0.02-fold over the control sample, respectively; p < 0.05, p < 0.001, p < 0.01, and p < 0.001, respectively, Fig. 2a). In addition, RCE at concentrations of 1.5, 3.0, 15.0, and 30.0 μg/mL significantly enhanced the expression of p-GSK3β (1.06 ± 0.15, 1.48 ± 0.10, 1.72 ± 0.29, 2.36 ± 0.31-fold over the control sample, respectively; NS, p < 0.01, p < 0.05, and p < 0.01, respectively; Fig. 2b and c, respectively) and p- GS (0.98 ± 0.12, 1.06 ± 0.09, 1.30 ± 0.08, and 1.47 ± 0.09-fold over the control sample, respectively; NS, NS, p < 0.01, and p < 0.001, respectively; Fig. 2b and d, respectively). These results indicate that RCE increased glycogen synthesis and expression of regulatory enzymes in HepG2 cells under high glucose conditions.

Fig. 2
figure 2

Effects of RCE on glycogen synthesis in HepG2 cells. HepG2 cells were cultured in 24-well plates and exposed to medium without serum for 24 h. The cells were then incubated with RCE (μg/mL) for 6 h or insulin (Ins, 100 nM) for 1 h before 14C (U)-d-glucose was added. The intensity of 14C in glycogen was analyzed (a). Expression levels of p-GSK3ß and p-GS were analyzed by western blotting (b). A quantitative analysis of the relative levels of p-GSK3ß (c) and p-GS (d) was conducted. The results represent the mean ± SEM (n = 3), ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. the sample without RCE

Full size image

RCE reduces lipogenesis and related gene expression

In addition to the impact of RCE on hepatic glycogen synthesis, the effect of RCE treatment on hepatic lipid metabolism was also examined. RCE at concentrations of 1.5, 3.0, 15.0, and 30.0 μg/mL significantly suppressed hepatic lipogenesis (0.90 ± 0.04, 0.79 ± 0.04, 0.57 ± 0.05, and 0.54 ± 0.05-fold, respectively; NS, p < 0.01, p < 0.001, and p < 0.001, respectively, compared to that of the control group; Fig. 3a). Consistently, we also observed that protein levels of C/EBP (1.02 ± 0.03, 0.98 ± 0.11, 0.64 ± 0.09, and 0.39 ± 0.09-fold for 1.5, 3.0, 15.0, and 30.0 μg/mL, respectively; NS, NS, p < 0.01, and p < 0.001, respectively, compared to that of the control group; Fig. 3b and c) and SREBP-1c (0.81 ± 0.07, 0.70 ± 0.08, 0.59 ± 0.07, and 0.57 ± 0.01-fold for 1.5, 3.0, 15.0 and 30.0 μg/mL, respectively; p < 0.05, p < 0.05, p < 0.01, and p < 0.001, respectively, compared to that of the control group; Fig. 3b and d) were significantly suppressed. Furthermore, RCE treatment also suppressed mRNA levels of lipogenesis-associated, including FAS, the key enzyme involved in fatty acid synthesis (0.67 ± 0.11, 0.60 ± 0.09, 0.33 ± 0.04, and 0.32 ± 0.05-fold for 1.5, 3.0, 15.0, and 30.0 μg/mL, respectively; NS, p < 0.05, p < 0.001, and p < 0.001, respectively, compared to that of the control group, Fig. 3e), and SREBP1c (0.78 ± 0.08, 0.74 ± 0.03, 0.64 ± 0.05, and 0.58 ± 0.07-fold for 1.5, 3.0, 15.0, and 30.0 μg/mL, respectively; p < 0.05, p < 0.001, p < 0.001, and p < 0.001, respectively, compared to that of the control group; Fig. 3f). These results indicate that RCE suppressed fat accumulation in hepatic cells under high glucose conditions. As a positive control, AICAR reduced protein levels of C/EBP (0.77 ± 0.11-fold over the control sample; NS; Fig. 3b and c) and SREBP (0.59 ± 0.02-fold over the control sample; p < 0.01; Fig. 3b and d), as well as gene expression of FAS (0.53 ± 0.12-fold over the control sample; p < 0.01; Fig. 3d) and SREBP1c (0.71 ± 0.06-fold over the control sample; p < 0.01; Fig. 3e).

Fig. 3
figure 3

Effects of RCE on TG content and expression of lipogenic enzymes in HepG2 cells. HepG2 cells were cultured in high-glucose (33 mM) medium containing Ins (100 nM) with or without the indicated concentration of RCE (μg/mL) or AICAR (2 mM). Lipogenesis (a), relative protein levels SREBP1and C/EBP (b), and gene expression (e and f) were measured. A quantitative analysis of the protein levels of SREBP1 (c) and C/EBP (d) was conducted. The results represent the mean ± SEM (n = 3), ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. the sample without RCE

Full size image

Compound C abolishes the effects of RCE on hepatic glycogenesis and lipogenesis

In order to investigate the mechanism underlying the effects of RCE, compound C and LY294002 were employed. RCE-induced glycogen biosynthesis was diminished upon inhibition of signaling by AMPK (from 1.31 ± 0.04 to 0.89 ± 0.04-fold compared with the control sample; p < 0.001; Fig. 4a) and PI3K (from 1.31 ± 0.04 to 0.83 ± 0.05-fold compared with the control sample; p < 0.001; Fig. 4a). In addition, the inhibitory effect of RCE on lipogenesis was nearly abolished by compound C (from 0.69 ± 0.07 to 0.93 ± 0.05-fold compared with the control sample; p < 0.05; Fig. 4b). However, no significant effect of LY294002 treatment was detected (from 0.69 ± 0.07 to 0.70 ± 0.05-fold compared with the control sample; NS; Fig. 4b). Similarly, compound C abolished the effects of RCE on p-ACC (from 1.47 ± 0.09 to 0.51 ± 0.03-fold compared with the control group; p < 0.001; Fig. 4c and d), SREBP1c (from 0.80 ± 0.01 to 0.99 ± 0.04-fold compared with the control group; p < 0.05; Fig. 4c and e), and p-GSK3ß (from 1.35 ± 0.08 to 0.94 ± 0.02-fold compared with the control group; p < 0.01; Fig. 4c and f). This result indicates that the regulatory effects of RCE on hepatic glycogen and lipid metabolism are associated with the AMPK signaling pathway.

Fig. 4
figure 4

Effects of LY294002 (LY) and compound C (CC) on glycogen synthesis and TG content in HepG2 cells. HepG2 cells were incubated in high-glucose medium (33 mM) for 16 h and then pretreated with RCE for 12 h or kinase inhibitors (20 Î¼M LY294002 or 10 Î¼M compound C) prior to RCE treatment (15 Î¼g/mL) for 1 h. Glycogen synthesis (a) and TG content (b) were measured. Expression levels of p-ACC, SREBP1c, and p-GSK3ß were measured by western blotting (c). A quantitative analysis of the protein levels of p-ACC (d), SREBP1c (e), and p-GSK3ß (f) was conducted. The results represent the mean ± SEM (n = 3). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. the sample without RCE; #p < 0.05, ## p < 0.01, and ###p < 0.001 vs. the RCE-treated sample

Full size image

RCE administration suppresses lipogenesis-related gene expression in the rat liver

To assess the effects of RCE treatment in vivo, a rodent model was employed. Hepatic C/EBP and SREBP1c protein levels (0.24 ± 0.07 and 0.72 ± 0.08-fold compared to the control group; p < 0.05, respectively; Fig. 5a, b, and c) were significantly decreased in the RCE-treated animals. Similarly, mRNA levels of lipogenesis-related genes FAS and SREBP1c in the rat liver were also suppressed by RCE treatment (0.55 ± 0.06 and 0.26 ± 0.02-fold compared to the control group; p < 0.01 and p < 0.001, respectively; Fig. 5d and e). These results indicate that the in vivo effects of RCE are similar to its in vitro effects.

Fig. 5
figure 5

Effects of RCE on lipogenic protein and gene expression in rat liver. Protein (a) and gene (d and e) expression levels of C/EBP and SREBP-1c were analyzed by western blotting and Q-PCR, respectively. A quantitative analysis of the protein levels of C/EBP (b) and SREBP-1c (c) was conducted. The results represent the mean ± SEM (n = 3). ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 vs. the sample without RCE

Full size image

Discussion

The liver is an important organ for whole-body energy homeostasis because of its regulation of glucose and lipid metabolism [12]. Hepatic AMPK activation suppresses anabolic metabolism, including cholesterol and fatty acid synthesis, and increases fatty acid oxidation by regulating gene expression and downstream enzymatic activities. Thus, hepatic AMPK activation is commonly regarded as a strategy for managing metabolic syndrome [12] and related symptoms, such as fatty liver. In a previous study, we showed that RCE increased hepatic AMPK activation [19]. In this study, RCE significantly increased AMPK activation and regulated glycogen synthesis and lipogenesis in hepatic cells. The hypolipidemic effect of RCE was verified by the decreased expression levels of genes involved in fatty acid biosynthesis (SREBP-1c, C/EBP, and FAS) and increased fatty acid β-oxidation (phosphorylation of ACC) in HepG2 cells. In addition, RCE inhibited protein and gene expression of lipogenesis-related genes (SREBP-1c, C/EBP, and FAS) in the rat liver. These results suggest that RCE regulates hepatic glycogen and lipid metabolism via the AMPK pathway (Fig. 6).

Fig. 6
figure 6

The regulation of RCE on hepatic glycogen and lipid metabolism. RCE regulates hepatic glycogen and lipid metabolism through the AMPK signaling pathway

Full size image

Biosynthesis of glycogen is decreased in hepatocytes under high glucose conditions [26] and patients with insulin resistance [27]. Impaired glucose metabolism is associated with hepatic lipid accumulation. However, most studies have focused on improving abnormal lipid metabolism rather than glycogen synthesis. In this study, we simulated hepatic insulin-resistant conditions by incubating HepG2 cells in 33 mM high-glucose medium. Pretreatment with RCE significantly increased glycogen synthesis under high glucose conditions (Fig. 2a). The effect of RCE is similar to that of thiazolidinedione, a clinical antidiabetic drug that increases hepatic glycogen content in diabetic rodents [28]. In addition, we showed that RCE significantly increased GSK3β phosphorylation at Ser9, thereby inhibiting its activity, which subsequently increased GS activity and glycogen biosynthesis in HepG2 cells (Fig. 2b, c, and d). These results indicate that RCE exerted a beneficial effect on hepatic glycogen metabolism under high glucose conditions. Although the PI3K/AKT signaling pathway is crucial in the regulation of glycogen biosynthesis [7], RCE treatment did not promote phosphorylation of AKT at T308 or S473 in our previous study [19]. These results are thus consistent with the effect of metformin, an AMPK activator, as an inhibitor of Akt phosphorylation under high glucose conditions [29]. Thus, improvement of glycogen synthesis by RCE is not dependent on the PI3K/AKT signaling pathway. In fact, phosphorylation of GSK3ß was also directly regulated by AMPK activation [30]. Based on these results, we suggest that RCE might increase glycogen synthesis via the AMPK-GSK3β -GS pathway, despite the fact that the physiological significance of such an effect is still unclear. Furthermore, a previous study mentioned that regulation of GSK3 activity in pancreatic beta cells enhanced cell viability and proliferation, an effect that would benefit patients with type I and II diabetes [31]. The possibility that RCE improves insulin sensitivity partially via the AMPK-GSK3 pathway in pancreatic beta cells requires further investigation.

The pathological mechanism of NAFLD is excessive lipid accumulation in the liver due to imbalanced fatty acid synthesis and oxidation [32], which are orchestrated by the interaction of multiple factors, including SREBP-1, an important transcriptional modulator involved in hepatic lipid metabolism that is involved in transcriptional regulation of lipogenic enzymes (FAS and ACC), regulation of fatty acid biosynthesis and VLDL assembly, and intracellular fatty acid trafficking [27, 33]. In addition, overexpression of hepatic SREBP-1 was shown to be associated with hyperlipidemia in rodent models of obesity and type II diabetes [12]. Here, we showed that RCE treatment significantly suppressed in vitro and in vivo SREBP-1c expression. In addition, SREBP1 expression was inhibited by AMPK activation [34]. Thus, we suggest that RCE regulated hepatic lipid accumulation, at least partially by suppression of SREBP-1c expression. Similarly, we found that RCE significantly increased hepatic AMPK activation, while it phosphorylated and inactivated downstream substrates of AMPK, including ACC and FAS. Phosphorylation of ACC suppressed conversion of acetyl-CoA to malonyl-CoA, which contributed to inhibited lipid synthesis, increased mitochondrial fatty acid oxidation, and insulin-sensitization [25]. This result suggests that the insulin-sensitizing effect of RCE might have been a result of activation of the AMPK-ACC signaling pathway. RCE exerted beneficial effects by inhibiting fat accumulation and promoting fat oxidation in the liver, suggesting that it might be a potential preventive agent for NAFLD.

Glycogen metabolism is crucial for long-term physical performance. We demonstrated that RCE improved glycogen metabolism, which implies that RCE could enhance the physical performance of diabetic patients. A recent study indicated that activation of AMPK by an herbal medicine produced beneficial effects in a rodent model of ethanol-induced hepatosteatosis [35]. Metformin, an AMPK activator, alleviated hepatic steatosis in obese mice [36]. With the capacity to activate AMPK, further studies are required to elucidate whether RCE can ameliorate hepatic steatosis in alcoholic patients. In humans, obesity and plasma TG concentration are significantly associated with the TG level in the liver [37]. Wang et al. indicated that RCE decreased the plasma concentration of TG in a rodent model [18]. Lee et al. indicated that RCE exerted antiadipogenic effects involved in endogenous antioxidant enzyme response and proline-mediated pentose phosphate pathway in differentiated adipocytes [38]. We showed that RCE decreased TG content in HepG2 cells. Taken together, these results suggest that RCE might be useful for the management of systemic lipid metabolism.

Conclusion

In this study, we demonstrated the ability of RCE to regulate glycogen and lipid metabolism in the liver. Our results suggest that R. crenulata might be a potential therapeutic agent for NAFLD.

Ethics approval and consent to participate

The animal experimental procedures were performed according to the Institutional Animal Care and Use Committee of the National Defense Medical Center (IACUC-11-055).

Consent for publication

Not applicable

Availability of data and materials

The data and materials have been presented in the main manuscript.

Abbreviations

RCE:

Rhodiola crenulata root extract

NAFLD:

nonalcoholic fatty liver disease

AMPK:

AMP-activated protein kinase

ACC:

acetyl-CoA carboxylase

GSK3β:

glycogen synthase kinase 3β

GS:

glycogen synthase

FAS:

fatty acid synthase

C/EBP:

CCAAT/enhancer-binding protein

SREBP-1c:

sterol regulatory element-binding protein 1c

TG:

triglycerides

References

  1. Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013;3(1):1–58.

    PubMed  PubMed Central  Google Scholar 

  2. Martin-Timon I, Sevillano-Collantes C, Segura-Galindo A, Del Canizo-Gomez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014;5(4):444–70.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Schmutz I, Albrecht U, Ripperger JA. The role of clock genes and rhythmicity in the liver. Mol Cell Endocrinol. 2012;349(1):38–44.

    Article  CAS  PubMed  Google Scholar 

  4. Weickert MO, Pfeiffer AF. Signalling mechanisms linking hepatic glucose and lipid metabolism. Diabetologia. 2006;49(8):1732–41.

    Article  CAS  PubMed  Google Scholar 

  5. Henriksen EJ, Dokken BB. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets. 2006;7(11):1435–41.

    Article  CAS  PubMed  Google Scholar 

  6. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51(5):1820–32.

    Article  PubMed  Google Scholar 

  7. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799–806.

    Article  CAS  PubMed  Google Scholar 

  8. Roach PJ, Depaoli-Roach AA, Hurley TD, Tagliabracci VS. Glycogen and its metabolism: some new developments and old themes. Biochem J. 2012;441(3):763–87.

    Article  CAS  PubMed  Google Scholar 

  9. Kusunoki M, Tsutsumi K, Hara T, Ogawa H, Nakamura T, Miyata T, Sakakibara F, Fukuzawa Y, Suga T, Kakumu S, et al. Correlation between lipid and glycogen contents in liver and insulin resistance in high-fat[ndash]fed rats treated with the lipoprotein lipase activator NO-1886. Metabolism. 2002;51(6):792–5.

    Article  CAS  PubMed  Google Scholar 

  10. Couturier K, Qin B, Batandier C, Awada M, Hininger-Favier I, Canini F, Leverve X, Roussel AM, Anderson RA. Cinnamon increases liver glycogen in an animal model of insulin resistance. Metabolism. 2011;60(11):1590–7.

    Article  CAS  PubMed  Google Scholar 

  11. Bardini G, Rotella C, Giannini S. Dyslipidemia and diabetes: reciprocal impact of impaired lipid metabolism and Beta-cell dysfunction on micro- and macrovascular complications. Rev Diabet Stud. 2012;9(2–3):82–93.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Viollet B, Foretz M, Guigas B, Horman S, Dentin R, Bertrand L, Hue L, Andreelli F. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol. 2006;574(Pt 1):41–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Foretz M, Viollet B. Regulation of hepatic metabolism by AMPK. J Hepatol. 2011;54(4):827–9.

    Article  PubMed  Google Scholar 

  14. Srivastava RA, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, Newton RS. AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J Lipid Res. 2012;53(12):2490–514.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 2009;9(5):407–16.

    Article  PubMed  Google Scholar 

  16. Lee SY, Li MH, Shi LS, Chu H, Ho CW, Chang TC. Rhodiola crenulata Extract Alleviates Hypoxic Pulmonary Edema in Rats. Evid Based Complement Alternat Med. 2013;2013:718739.

    PubMed  PubMed Central  Google Scholar 

  17. Li WL, Zheng HC, Bukuru J, De Kimpe N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol. 2004;92(1):1–21.

    Article  CAS  PubMed  Google Scholar 

  18. Wang J, Rong X, Li W, Yang Y, Yamahara J, Li Y. Rhodiola crenulata root ameliorates derangements of glucose and lipid metabolism in a rat model of the metabolic syndrome and type 2 diabetes. J Ethnopharmacol. 2012;142(3):782–8.

    Article  CAS  PubMed  Google Scholar 

  19. Lee S-Y, Lai F-Y, Shi L-S, Chou Y-C, Yen IC, Chang T-C. Rhodiola crenulata extract suppresses hepatic gluconeogenesis via activation of the AMPK pathway. Phytomedicine. 2015;22(4):477–86.

    Article  CAS  PubMed  Google Scholar 

  20. Hasenour CM, Berglund ED, Wasserman DH. Emerging role of AMP-activated protein kinase in endocrine control of metabolism in the liver. Mol Cell Endocrinol. 2013;366(2):152–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, Rudolph D, Schutz G, Yoon C, Puigserver P, et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 2001;13(413):179–83.

    Article  Google Scholar 

  22. Chang WL, Ho YH, Huang YC, Huang SF, Lin JY, Lin HC, Chang TC. The Inhibitory Effect of Ginsenoside Rg1 on Glucose and Lipid Production in Human HepG2 Cells. Adaptive Med. 2013;5(4):181–8.

    Article  CAS  Google Scholar 

  23. Kim JJ, Tan Y, Xiao L, Sun YL, Qu X. Green tea polyphenol epigallocatechin-3-gallate enhance glycogen synthesis and inhibit lipogenesis in hepatocytes. BioMed Res Int. 2013;2013:920128.

    PubMed  PubMed Central  Google Scholar 

  24. Lee SY, Shi LS, Chu H, Li MH, Ho CW, Lai FY, Huang CY, Chang TC. Rhodiola crenulata and Its Bioactive Components, Salidroside and Tyrosol, Reverse the Hypoxia-Induced Reduction of Plasma-Membrane-Associated Na,K-ATPase Expression via Inhibition of ROS-AMPK-PKCξ Pathway. Evid Based Complement Alternat Med. 2013;2013:1–15.

    Google Scholar 

  25. Fullerton MD, Galic S, Marcinko K, Sikkema S, Pulinilkunnil T, Chen ZP, O'Neill HM, Ford RJ, Palanivel R, O'Brien M, et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med. 2013;19(12):1649–54.

    Article  CAS  PubMed  Google Scholar 

  26. Lin CL, Lin JK. Epigallocatechin gallate (EGCG) attenuates high glucose-induced insulin signaling blockade in human hepG2 hepatoma cells. Mol Nutr Food Res. 2008;52(8):930–9.

    Article  CAS  PubMed  Google Scholar 

  27. Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56(4):952–64.

    Article  CAS  PubMed  Google Scholar 

  28. Upton R, Widdowson PS, Ishii S, Tanaka H, Williams G. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. Br J Pharmacol. 1998;125(8):1708–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, Schonbeck U, Libby P. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol. 2006;26(3):611–7.

    Article  CAS  PubMed  Google Scholar 

  30. Choi SH, Kim YW, Kim SG. AMPK-mediated GSK3beta inhibition by isoliquiritigenin contributes to protecting mitochondria against iron-catalyzed oxidative stress. Biochem Pharmacol. 2010;79(9):1352–62.

    Article  CAS  PubMed  Google Scholar 

  31. Mussmann R, Geese M, Harder F, Kegel S, Andag U, Lomow A, Burk U, Onichtchouk D, Dohrmann C, Austen M. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J Biol Chem. 2007;282(16):12030–7.

    Article  CAS  PubMed  Google Scholar 

  32. Stienstra R, Duval C, Muller M, Kersten S. PPARs, Obesity, and Inflammation. PPAR Res. 2007;2007:95974.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol. 2006;290(5):G852–858.

    Article  CAS  PubMed  Google Scholar 

  34. Foretz M, Ancellin N, Andreelli F, Saintillan Y, Grondin P, Kahn A, Thorens B, Vaulont S, Viollet B. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes. 2005;54(5):1331–9.

    Article  CAS  PubMed  Google Scholar 

  35. Mandal S, Mukhopadhyay S, Bandhopadhyay S, Sen G, Biswas T. 14-Deoxyandrographolide alleviates ethanol-induced hepatosteatosis through stimulation of AMP-activated protein kinase activity in rats. Alcohol. 2014;48(2):123–32.

    Article  CAS  PubMed  Google Scholar 

  36. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000;6(9):998–1003.

    Article  CAS  PubMed  Google Scholar 

  37. Kamath S, Chavez AO, Gastaldelli A, Casiraghi F, Halff GA, Abrahamian GA, Davalli AM, Bastarrachea RA, Comuzzie AG, Guardado-Mendoza R, Jimenez-Ceja LM, Mattern V, Paez AM, Ricotti A, Tejero ME, Higgins PB, Rodriguez-Sanchez IP, Tripathy D, DeFronzo RA, Dick Jr EJ, Cline GW, Folli F. Coordinated Defects in Hepatic Long Chain Fatty Acid Metabolism and Triglyceride Accumulation Contribute to Insulin Resistance in Non-Human Primates. PLoS One. 2011;6(11):e27617.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Lee OH, Kwon YI, Apostolidis E, Shetty K, Kim YC. Rhodiola-induced inhibition of adipogenesis involves antioxidant enzyme response associated with pentose phosphate pathway. Phytother Res. 2011;25(1):106–15.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This work was supported by Grants from the Ministry of Science and Technology (MOST 104-2320-B-016-003 to S.-Y. L.) and the Ministry of National Defense (MAB-104-017 and MAB-103-M078 to S.-Y. L.), Taipei, Taiwan, ROC.

Funding

The Ministry of Science and Technology (MOST 104-2320-B-016-003 to S.-Y. L.) and the Ministry of National Defense (MAB-104-017 and MAB-103-M078 to S.-Y. L.), Taipei, Taiwan, ROC.

Author information

Authors and Affiliations

  1. Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan

    Kuen-Tze Lin & Shih-Yu Lee

  2. Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

    Kuen-Tze Lin

  3. Department of Neurosurgery, Taichung Armed Forces General Hospital, Taichung, Taiwan

    Shih-Wei Hsu

  4. Graduate Institute of Aerospace and Undersea Medicine, National Defense Medical Center, Taipei, Taiwan

    Feng-Yi Lai & Shih-Yu Lee

  5. Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan

    Tsu-Chung Chang

  6. Department of Biotechnology, National Formosa University, Yunlin, Taiwan

    Li-Shian Shi

Authors
  1. Kuen-Tze Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shih-Wei Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Feng-Yi Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tsu-Chung Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li-Shian Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shih-Yu Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shih-Yu Lee.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SYL, KTL, and SWH participated in the concept of the study and the experimental design. KTL, FYL, and LSS involved in laboratory works and data analysis. KTL wrote the manuscript and TCC reviewed it. All authors read and approved the final manuscript.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, KT., Hsu, SW., Lai, FY. et al. Rhodiola crenulata extract regulates hepatic glycogen and lipid metabolism via activation of the AMPK pathway. BMC Complement Altern Med 16, 127 (2016). https://doi.org/10.1186/s12906-016-1108-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12906-016-1108-y

Keywords

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us